Community

The Rise of Peptide-Based Longevity Protocols Among Caribbean Biohackers

From Barbados to Curaçao, small networks of self-experimenters are running rigorous, well-documented protocols — and producing data the academic world is starting to notice.

JA
Jules Adekunle
Community Editor
Share

In a converted beachfront clinic outside Bridgetown, twelve people gather on the first Sunday of every month. They are not patients. They are not, strictly speaking, researchers. They are participants in what may be one of the most carefully documented citizen-science longevity protocols in the region.

The group — informally calling itself the Atlantic Longevity Cohort — runs a rolling 12-month protocol combining well-characterized peptides (epitalon, MOTS-c, GHK-Cu) with structured exercise, time-restricted feeding, and quarterly biomarker panels. Every participant is over 40. Every participant pays for their own labs. And every participant logs data into a shared, anonymized spreadsheet that now spans more than three years of continuous measurement.

"We log everything. Blood panels, sleep, HRV, grip strength. The data is the protocol."

Why the Caribbean

Several factors converge to make the region a quiet hub for this kind of work. Regulatory frameworks for research peptides are clearer than in some Western jurisdictions. Costs for advanced biomarker panels — telomere length, glycan age, inflammatory markers — are lower. And a culture of holistic medicine has produced a patient population genuinely interested in long-form, multi-month interventions.

"We log everything. Blood panels, sleep, HRV, grip strength. The data is the protocol," said one cohort lead, who asked not to be named due to professional considerations.

The data, and its limits

A growing number of academic gerontologists have begun reviewing this kind of citizen-science data with cautious interest. The cohort is small (n = 12), unblinded, and self-selected — disqualifying it from any formal clinical conclusion. But the rigor of measurement is, in some respects, better than typical phase I trials: continuous biomarker tracking, complete drug accountability, and no patient loss to follow-up.

Dr. Aimée Laval, a gerontologist at the University of the West Indies who has consulted informally with several similar groups, frames it carefully: "These are not clinical trials. They are well-instrumented case series. That has a place in hypothesis generation, especially in a field where formal funding is scarce."

What's actually being studied

The most-watched compounds in these protocols are not the newest. They are the ones with the longest preclinical paper trails:

  • Epitalon, for its pineal-axis and telomerase-adjacent mechanisms
  • MOTS-c, for mitochondrial signaling and insulin sensitivity
  • GHK-Cu, for skin and extracellular-matrix endpoints

None of these are approved therapeutics. None should be construed as treatment recommendations. But the community is asking sharper questions, with better instrumentation, than it was even three years ago — and the academic world is, slowly, paying attention.

#Community#Longevity#Biohacking#Caribbean
JA
Written by
Jules Adekunle
Community Editor

Reports on biohacker communities, longevity protocols, and citizen science.

Discussion

Verified researchers only

Comments are open to verified Protides community members.
Community verification is coming soon.

Talk to our ambassador
on WhatsApp